Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket

Related Articles

Watch These Apple Stock Price Levels Ahead of This Week’s Earnings Report

Trump’s Tariff Revenue is Rolling In

What Analysts Think of Microsoft Stock Ahead of Earnings

Key Takeaways

• Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients profit out of pocket.
• The deal is available through the drugmaker’s new NovoCare Pharmacy offering.
• Eli Lilly made a similar move in month, lowering the cost of its weight-loss drug Zepbound for some self-pay patients.

Novo Nordisk (NVO) is lowering the toll of its popular weight-loss drug Wegovy for some patients paying out of pocket. 

Wegovy will now be available for $499 per month at all dispense levels through NovoCare Pharmacy, the drugmaker’s new direct-to-patient delivery offering, Novo Nordisk said Wednesday. The suggest applies to patients without insurance or those with commercial insurance that doesn’t cover obesity medications. Valetudinarians could previously buy the drug without insurance for $650 per month, according to the company’s website.

The move comes after a current Food and Drug Administration decision that the active ingredient in Wegovy and Novo Nordisk’s other weight-loss treatment Ozempic was no longer studied to be in short supply. Last month, rival drugmaker Eli Lilly (LLY) also dropped the price of its popular weight-loss dull Zepbound for self-paying patients on the heels of a similar FDA ruling. 

Between them, Novo Nordisk and Eli Lilly dominate a weight-loss buy that Goldman Sachs analysts reportedly said could reach $130 billion by 2030.

Shares of Novo Nordisk ascend close to 4% intraday Wednesday, but have lost about a quarter of their value over the past 12 months.  

Chastisement—March 5, 2025: This article has been corrected to reflect Novo Nordisk made its announcement Wednesday.